Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Tumors Stories

2014-01-07 12:28:59

Alex's Lemonade Stand Foundation Supports Cancer Vaccine Research at the University of Maryland. COLLEGE PARK, Md., Jan. 7, 2014 /PRNewswire-USNewswire/ -- In 2004, a form of cancer known as neuroblastoma claimed the life of Alexandra (Alex) Scott, a little girl who gained national attention for using her lemonade stand to raise money for cancer research. Now, the organization established in her memory, the Alex's Lemonade Stand Foundation (ALSF), has awarded University of Maryland...

2014-01-03 15:47:18

A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA). The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer. But research published today in the American Heart Association’s journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of...

2013-12-27 10:33:27

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report. In the study, published online today in Cell Reports, scientists found that inhibiting the action of a protein called BRD4 caused cancer cells to die in a mouse model of malignant peripheral nerve sheath tumors (MPNSTs). "This study identifies a potential new therapeutic target to combat MPNST, an incurable...

2013-12-10 10:35:18

Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research...

2013-12-09 23:01:32

St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor Memphis, Tenn. (PRWEB) December 09, 2013 Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other...

Genetically Modified Cells Produce Long-term Remissions
2013-12-09 06:46:50

University of Pennsylvania School of Medicine Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to...

2013-12-07 16:20:24

- Findings Presented at 55th American Society of Hematology (ASH) Annual Meeting - LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma. In an oral...

2013-12-07 08:20:41

Researchers Unveil First Results in Adult ALL Patients: All Five Patients Had Complete Response to Therapy NEW ORLEANS, Dec. 7, 2013 /PRNewswire/ -- Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies...

2013-12-06 11:13:12

Researchers describe a novel mechanism by which glioblastoma tumors resist targeted therapies A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in...

Study Finds Drug-Resistant Melanoma Treatments May Be Enhanced
2013-11-22 09:27:11

April Flowers for redOrbit.com - Your Universe Online More than 8,000 Americans are killed each year by melanoma -- the deadliest form of skin cancer. The presence of mutations in a gene known as the BRAF gene drives approximately 40 percent of advanced melanoma tumors. New medications, called BRAF inhibitors, have shown an ability to rapidly shrink melanoma tumors, however BRAF-mutated tumors often resist early treatment and only partially respond to BRAF inhibitors, which leaves...